KOLINPHARMA
brevetti
Patents
Our products are unique.
New patent
Patent is an amazing tool for enterprises, which allows them to protect their own investments in research and innovation and to acquire additional economical resources through the economic management of its exploitation rights.

Today many companies’ value consists of 90% of intangible assets, mainly composed by industrial property rights. A company with the patent protection is in the position of preventing another company to produce, commercialize and sell a product or a competition, violating its own patent protection.

The patents portfolio is a demonstration of the high quality, specialization and technology capabilities of the company. A patent determines a company enrichment, and also its help to increase the market position.

To date, Kolinpharma has obtained 5 industrial patents in Italy, 3 patents in 12 new European countries beyond Italy, 5 patents in the United States and 1 in Israel, a conquest that is a source of great pride in countries considered a worldwide reference in scientific research and of great importance in the world of nutraceuticals which testifies to the seriousness and accuracy research and confirms the ability of the R&D team to study innovative formulations and develop effective products, based on the most current scientific evidence in the various reference areas.


Almetax patented

ALMETAX
Industrial invention patent
n° ITA 0001425921 - n° EU 3182966
Granted because of the recognized innovation and uniqueness of the composition in the prevention and treatment of metabolic alterations related to climacteric and menopause.
Patents validated in: Belgium, France, Germany, Great Britain, Spain, Switzerland / Li, Turkey, Italy. View the document ITA
Ivuxur patented

IVUXUR
Industrial invention patent
n° US 10,300,099 B2
Granted because of the recognized innovation and uniqueness of the composition specific for the treatment and prevention of urinary tract infections. View the document USA
Miledix patented

MILEDIX
Formulation patent
n° ITA 10 2018 000020932
Granted as the innovation, uniqueness and synergy of the components in the treatment of menstrual cycle disorders have been recognized.
Dolatrox patented

DOLATROX

Industrial invention patent
n° US 10,548,937 B2
Granted because of the recognized innovation and uniqueness of the composition in the treatment of arthropathies and osteoarthritis.
Xinepa patented
XINEPA
Formulation patent
n° ITA 0001425919 - n° US 9,980,940 - n° ISR 250594
n° EU 3182965
Technology patent

n° ITA 102015000010454 - n° US 10,413,526 - n° EU 3277273
The formulation patent was granted for demonstrating, in a statistically significant way, the synergistic efficacy of the active ingredients of XINEPA, for a composition used in the treatment of neuropathies and/or neuropathic pain.
Patents validated in: Belgium, France, Germany, Great Britain, Spain, Switzerland / Li, Turkey, Israel, Italy, USA.

Technology patent was granted for demonstrating the innovation in the technology behind the formulation.
Patents validated in: Austria, Denmark, Germany, Great Britain, Poland, Portugal, Sweden, Italy, USA. View the document ITA View the document USA View the document USA View the document IL
Milesax patented
MILESAX
Industrial invention patent
n° ITA 0001425920 - n° US 10583120
Granted because of the recognized innovation and uniqueness of the composition, with muscle relaxant and anti-inflammatory activity. View the document ITA View the document USA
Related news